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Abstract
Fifty years after the recognition of the Li–Fraumeni syndrome (LFS), our perception of cancers related to germline
alterations of TP53 has drastically changed: (i) germline TP53 alterations are often identified among children with cancers, in
particular soft-tissue sarcomas, adrenocortical carcinomas, central nervous system tumours, or among adult females with
early breast cancers, without familial history. This justifies the expansion of the LFS concept to a wider cancer predisposition
syndrome designated heritable TP53-related cancer (hTP53rc) syndrome; (ii) the interpretation of germline TP53 variants
remains challenging and should integrate epidemiological, phenotypical, bioinformatics prediction, and functional data; (iii)
the penetrance of germline disease-causing TP53 variants is variable, depending both on the type of variant (dominant-
negative variants being associated with a higher cancer risk) and on modifying factors; (iv) whole-body MRI (WBMRI)
allows early detection of tumours in variant carriers and (v) in cancer patients with germline disease-causing TP53 variants,
radiotherapy, and conventional genotoxic chemotherapy contribute to the development of subsequent primary tumours. It is
critical to perform TP53 testing before the initiation of treatment in order to avoid in carriers, if possible, radiotherapy and
genotoxic chemotherapies. In children, the recommendations are to perform clinical examination and abdominal ultrasound
every 6 months, annual WBMRI and brain MRI from the first year of life, if the TP53 variant is known to be associated with
childhood cancers. In adults, the surveillance should include every year clinical examination, WBMRI, breast MRI in
females from 20 until 65 years and brain MRI until 50 years.
Introduction
From Li–Fraumeni syndrome to heritable
TP53-related cancers
Heterozygous germline TP53 alterations were identified in
1990 in the Li–Fraumeni syndrome (LFS), described in
1969 by Frederick Li and Joseph Fraumeni [1–3]. The p53
protein normally acts as a guardian of the genome, and if
DNA damage occurs, p53 triggers a response based on
transcription regulation of numerous genes involved in cell
cycle, DNA repair, apoptosis, senescence and cellular
metabolism. LFS is characterised by a strong familial
aggregation of cancers, early-onset of tumours and wide
tumour spectrum, including the so-called core LFS cancers:
soft-tissue sarcomas (STS), osteosarcomas, adrenocortical
carcinomas (ACC), central nervous system (CNS) tumours
and very early-onset female breast cancers, occurring before
31 years. Fifty years after the initial clinical recognition of
the syndrome, germline alterations of TP53 are mainly
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identified among children with cancers or among adult
females with breast cancers, in both cases often without
familial history of cancer. For this reason, our perception of
cancers related to germline alterations of TP53 has drasti-
cally changed through time [4–6]. The diversity of clinical
presentations associated with germline TP53 alterations
justifies the expansion of the LFS concept to a wider cancer
predisposition syndrome designated heritable TP53-related
cancer (hTP53rc) syndrome. Criteria for germline TP53
variant screening named ‘Chompret criteria’ have been
sequentially updated ([6]; see below recommendation 1).
Regardless of familial history, the detection rate of disease
causing germline TP53 variants has been estimated to be:
50–80% in children presenting with ACC [6–9] or choroid
plexus carcinomas [6, 10]; up to 73% in children with
rhabdomyosarcoma of embryonal anaplastic subtype [11]
and between 3.8 and 7.7% in females with breast carcinoma
before 31 years of age [12]. These data demonstrate that
familial history of cancer should not be mandatory when
considering genetic testing of TP53. The frequency of
presentations without familial cancer history is explained
both by the contribution of de novo variants to hTP53rc
syndrome, which has been estimated to be between 7 and
20% [13, 14], and the incomplete penetrance of germline
TP53 variants. Beside the Chompret criteria, recent reports
and experience of certain centres justify to extend TP53
testing to other clinical presentations suggestive of a
germline TP53 alteration: Children and adolescents with
hypodiploid acute lymphoblastic leukaemia [15, 16],
otherwise unexplained sonic hedgehog-driven medullo-
blastoma [17], jaw osteosarcoma (see below recommenda-
tion 2) and patients who develop a second primary tumour
within the radiotherapy field of a first core TP53
tumour which occurred before 46 years (see below recom-
mendation 3).
Interpretation of germline TP53 variants
Because the TP53 gene is currently included in several
cancer gene panels broadly used in genetic testing, the
number of TP53 tests performed in non-suggestive clinical
situations has exponentially increased. Whereas the inter-
pretation of TP53 variants predicted to result in loss of
function, such as nonsense or frameshift deletions or
insertions, is usually obvious, the interpretation of missense
variants, representing the majority, is often challenging and
requires specific expertise. The most common consequence
of germline variants causing hTP53rc syndrome is the
functional inactivation of the protein. Classification of TP53
missense variants, in agreement with the ACMG/AMP
guidelines, is based on several considerations including
phenotypical data (identified in patients fulfilling the
Chompret criteria); frequency of the variant in the general
population, as reported by the Genome Aggregation Data-
base (https://gnomad.broadinstitute.org/), bioinformatics
predictions of the variant impact on protein or RNA spli-
cing using different algorithms, and functional analyses of
the variants performed using different in vitro assays per-
formed either in yeast or cultured cells [18–21] (http://p53.
iarc.fr/). Optimised and stringent ACMG/AMP criteria for a
specific classification of germline TP53 variants, integrating
the above considerations, are being developed by a TP53
variant curation expert panel, under the umbrella of
ClinGen. This will allow a progressive allocation or re-
classification of TP53 variants into the different ACMG/
AMP classes. Since the distinction between class 5
(pathogenic) and class 4 (likely pathogenic) variants is
particularly subtle for TP53 variants, these variants are
designated in the current ERN guideline as ‘disease-caus-
ing’ variants.
The question of mosaicism
The presence of mosaic TP53 alterations should be con-
sidered in patients with sporadic cancers strongly suggestive
of a disease-causing TP53 variant, such as childhood ACC,
choroid plexus carcinoma, and breast cancer before 31 years
of age and in patients with multiple primary tumours
belonging to the TP53 core tumour spectrum [14]. The
absence of detectable TP53 variants after analysis of blood
DNA using NGS, even performed at a high depth, does not
guarantee the absence of mosaic alterations which can be
restricted to other tissues than blood. Therefore, a complete
screening for TP53 disease causing variants in highly sug-
gestive situations should include analysis of tumour tissue,
which is so far not systematically performed. In contrast, the
detection of a TP53 variant in a small fraction of NGS reads
from blood DNA does not always correspond to a mosaic
alteration [22–25] and molecular geneticists should be
aware of two pitfalls: the first corresponds to circulating
tumour DNA, commonly observed in patients with meta-
static cancers. For instance, the detection of a TP53 variant
in the blood from a patient with metastatic high grade ser-
ous ovary carcinoma is likely to correspond to circulating
tumour DNA, considering the very high frequency of
somatic TP53 alterations in these malignancies (>95%); the
second is due to clonal haematopoiesis, corresponding to
the occurrence, in hematopoietic stem cells of somatic TP53
alterations conferring a growth advantage. Clonal haema-
topoiesis was initially reported in patients over 70 years of
age, but can be detected from 30 years of age. The fre-
quency of clonal haematopoiesis is increasing with age,
tobacco use and exposure to chemotherapy or radiotherapy
[22–25]. Therefore, when a TP53 variant is detected in a
small fraction of NGS reads from blood, it is critical, before
concluding that the presence represents a mosaic TP53
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alteration, to respect the following rules: (i) consider the
clinical presentation (suggestive or not of the presence of a
disease-causing TP53 variant) and medical history (treat-
ments, metastases, etc…) and (ii) confirm the presence of
the variant in the tissue from which the tumour originated.
Further confirmation in an unaffected tissue with no lym-
phocyte content, such as a hair follicle, skin biopsy or nail
clippings, should also be considered if circulating tumour
DNA is suspected from metastatic disease.
Cancer risk associated with germline TP53 variants
A challenge when dealing with TP53 variant carriers is to
estimate the cancer risk or penetrance associated with each
specific TP53 variant, and this cancer risk has recently been
revisited. Indeed, the cumulative cancer incidence of
germline disease-causing TP53 variants was initially cal-
culated using information mainly from familial cases and
was estimated to 73–100% by age 70, with risks close to
100% in women [26–28]. The predominance of familial
cases likely results in an ascertainment bias and an over-
estimation of disease penetrance. This should be regarded in
perspective with the prevalence in the general population of
germline disease-causing TP53 variants, which was recently
estimated, based on a conservative approach, to be in the
magnitude of 1 among 4500 individuals [29]. In childhood,
the main tumour risks are ACC, STS, osteosarcomas and
CNS tumours whereas the main tumour risk in adults cor-
responds to female breast cancers, female TP53 variant
carriers have an excessively high risk of developing breast
cancer before 31. There is no known elevated risk of male
breast cancer [4–6, 26–28, 30]. There is a perception that
colorectal cancer is associated with germline pathogenic
TP53 variants [31–33]. However, the corresponding studies
suffer from methodological limitations and interpretation of
some reported TP53 variants is problematic. Families with a
germline TP53 variant and an additional history of color-
ectal cancer in the pedigree may have increased risk of
colorectal cancer. This increased risk is, however, not
associated with the TP53 variant itself and, on the basis of
the published studies, a high risk of colorectal cancer can be
confidently excluded in carriers of disease-causing TP53
variants.
The penetrance of germline disease-causing TP53 var-
iants is variable. One factor explaining the variability of this
penetrance is the type of the variant itself: some of the p53
proteins bearing missense mutations are classified as
dominant-negative due to their ability to complex and
reduce the transcriptional activity of wild-type p53 protein,
producing malfunctioning or non-functioning p53 tetra-
mers. These dominant-negative missense TP53 variants are
usually detected in families with childhood cancers and are
generally highly penetrant. In contrast, null variants
(frameshift or nonsense variants, splicing variants, large
genomic rearrangements, and non-dominant-negative mis-
sense variants), are predominantly identified in families
with mostly adult cancers and have a lower disease pene-
trance [6]. A remarkable example of a low penetrant, but
still disease-causing variant, is the non-dominant-negative
missense p.Arg337His variant, present in 0.3% of the
population from Southern Brazil and associated with a
founder effect [34–36]. The difference in the clinical
severity between dominant-negative missense variants and
the remaining ones is explained by a difference in their
biological impact on the p53 transcriptional activity. Indeed,
measurement of the transcriptional response to DNA
damage in cells harbouring heterozygous TP53 variants, has
shown that dominant-negative missense variants have a
more drastic impact on p53 DNA binding and transcrip-
tional response to DNA damage, than the other types of
heterozygous alterations [19]. The clinical annotation of the
variants and updated functional data should allow progres-
sively, dichotomising disease-causing TP53 variants in
‘high cancer risk’ and ‘low cancer risk’ alleles.
The phenotypic variability observed within the same
family (e.g. a child affected with cancer and the parent,
carrier of the same variant, being not affected in childhood)
strongly supports the existence of genetic modifying factors
and their identification represents, at the present time, a top
priority in the field. It is more and more evident that phe-
notypic expression in carriers of TP53 disease-causing
variants is also dependent on environmental factors, as
germline TP53 variants may turn p53 into a protein per-
missive to oncogenic stress.
The impact of radio and chemotherapy on the
development of subsequent primary tumours
Germline TP53 variant carriers have a remarkably high
incidence of subsequent primary tumours, which may occur
in more than 40% of TP53 variant carriers [6, 27]. Sub-
sequent primary tumours often develop after the exposure of
TP53 variant carriers to radio and/or chemotherapy treat-
ments. The demonstration of the contribution of radio-
therapy and conventional chemotherapy to the development
of subsequent primary tumours in these carriers came from
consistent observations of sequential development of mul-
tiple tumours after treatment by chemo- or radiotherapy of a
first tumour and the development of tumours within the
radiotherapy field [6]. A cause-effect was strongly sup-
ported by studies of the impact of chemo- and radiotherapy
in lymphocytes with wild-type or mutant TP53 genotype
and LFS mouse models [37]. Therefore, in cancer patients,
testing for disease-causing TP53 variants must absolutely
take place before starting treatment and if a disease-causing
TP53 variant is found, priority should be given to surgical
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or ablative treatments, avoiding radiotherapy when possible
and using preferably non-genotoxic chemotherapies.
Surveillance protocols
Surveillance protocols for carriers bearing disease-causing
TP53 variants have recently been elaborated in the frame-
work of an international consortium coordinated by Cana-
dian and US teams [38, 39]. These protocols indicate that
carriers should undergo abdominal ultrasound every
3–4 months, annual whole-body MRI (WBMRI) and annual
brain MRI (the first with gadolinium enhancement) from the
first year of life. Additionally, female carriers should
undergo annual breast MRI from the age of 20 years
onwards. The option of risk-reducing mastectomy may be
discussed on a case-by-case basis [39]. Several international
studies, mostly performed without gadolinium-based con-
trast agents (GBCAs), have confirmed the efficiency of
WBMRI, with an overall estimated detection rate of 7% for
new and localised primary cancers on a first prevalent screen
[40–46]. Given that GBCAs may be retained for months or
years in several organs, multiple GBCAs administrations
should probably be avoided in germline TP53 variant car-
riers and only macrocyclic GBCAs, which are apparently
less retained in the body [47], should be used.
Scope of the guidelines
These guidelines have been elaborated by members of the
European Reference Network (ERN) on the Genetic
Tumour Risk Syndromes (GENTURIS) in order to integrate
the available information with clinical utility and to assist
health care professionals in the identification and manage-
ment of patients with germline disease-causing TP53 var-
iants, causing heritable TP53-related cancer (hTP53rc)
syndrome. In particular, these guidelines take into account
the diversity of clinical presentations associated with
germline TP53 variants, the variability of the TP53 variant
penetrance, the role of radiotherapy and chemotherapy in
the development of subsequent primary tumour and the
medical benefit of surveillance protocols. These guidelines
do not signify nor intend to be a legal standard of care, they
should support clinical decision making, but never replace
clinical professionals. This is particularly critical for
hTP53rc syndrome, considering the diversity of clinical
expression related to germline TP53 variants.
Methods followed
The ERN GENTURIS hTP53rc syndrome guideline was
established by molecular and clinical geneticists and clin-
icians with expertise in paediatrics, oncology, or radiology,
as well as affected individuals and parent representatives.
The Guideline Development Group was supported by a
Core Writing Group composed of ERN GENTURIS HCP
members from different member states and who are
recognised experts and specialised in molecular oncobiol-
ogy and/or clinical practice and/or in the diagnosis and
management of hTP53rc. The Core Writing Group leads
had joint meetings with a Patient Advisory Group com-
posed of affected individuals and parent representatives that
have experience with hTP53rc syndrome. The elaboration
of these guidelines has then actively involved external
experts from different speciality areas that are relevant to
the scope of the guideline.
The guidelines were elaborated on the basis of 337
published articles extracted from Pubmed, using the fol-
lowing terms: (screening [title/abstract] OR surveillance
[title/abstract] OR detection [title/abstract]) AND (LFS[title]
OR Li–Fraumeni [Title] OR TP53 [title]) AND ‘humans’
[MeSH Terms]. Additional articles were requested from
experts in the field and references of all the articles were
considered. As is typical for many rare diseases, the volume
of peer-reviewed evidence available to consider for these
guidelines was small and came from a limited number of
articles, which typically reported on small samples or series.
To balance the weight of both published evidence and
quantify the wealth of expert experience and knowledge, we
have used for evidence grading the following scale: (i)
strong evidence: consistent evidence and new evidence
unlikely to change recommendation and expert consensus;
(ii) moderate evidence: expert consensus or majority deci-
sion but with inconsistent evidence or significant new evi-
dence expected and (iii) weak evidence: inconsistent
evidence AND expert agreement.
Recommendations
Cancer patients who should be tested for germline
disease-causing TP53a
Recommendation 1 All patients who meet the modified ‘Chompret Criteria’ should be
tested for germline TP53 variants:
• Familial presentation: proband with a TP53 core tumour (breast
cancer, soft-tissue sarcoma, osteosarcoma, central nervous system
tumour, adrenocortical carcinoma) before 46 years AND at least
one first- or second-degree relative with a core tumour before 56
years; or
• Multiple primitive tumours: proband with multiple tumours,
including 2 TP53 core tumours, the first of which occurred before
46 years, irrespective of family history; or
• Rare tumours: patient with adrenocortical carcinoma, choroid
plexus carcinoma, or rhabdomyosarcoma of embryonal anaplastic
subtype, irrespective of family history; or
• Very early-onset breast cancer: Breast cancer before 31 years,
irrespective of family history
Recommendation 2 Children and adolescents should be tested for germline TP53
variants if presenting with:
• Hypodiploid acute lymphoblastic leukaemia (ALL); or
• Otherwise unexplained sonic hedgehog-driven medulloblastoma;
or
• Jaw osteosarcoma
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Table (continued)
Recommendation 3 Patients who develop a second primary tumour, within the
radiotherapy field of a first core TP53 tumour which occurred
before 46 years, should be tested for germline TP53 variants
Recommendation 4 a. Patients older than 46 years presenting with breast cancer without
personal or familial history fulfilling the ‘Chompret Criteria’ should
not be tested for germline TP53 variants
b. Any patient presenting with isolated breast cancer and not
fulfilling the ‘Chompret Criteria’, in whom a disease-causing TP53
variant has been identified, should be referred to an expert multi-
disciplinary team for discussion
Recommendation 5 Children with any cancer from southern and south-eastern Brazilian
families should be tested for the p.R337H Brazilian founder
germline TP53 variant
aTesting for disease-causing TP53 variants should be performed before starting treatment in
order to avoid in variant carriers, if possible, radiotherapy and genotoxic chemotherapy and
to prioritise surgical treatments.
Pre-symptomatic testing recommendations
Recommendation 6 Adult first-degree relatives of individuals with germline disease-
causing TP53 variants should be offered testing for the same germline
TP53 variant
Recommendation 7 The testing in childhood, from birth, of first-degree relatives of
individuals with germline disease-causing TP53 variants should be
systematically offered, if updated knowledge, based on databases and
registries, shows that the variant can be considered as a high cancer
risk TP53 variant conferring a high cancer risk in childhood:
• The index case has developed a childhood cancer; or
• Childhood cancers have been observed within the family; or
• This variant has already been detected in other families with
childhood cancers; or
• This variant corresponds to a dominant-negative missense variant
Recommendation 8 The testing in childhood of first-degree relatives of individuals with
germline disease-causing TP53 variants should not be systematically
offered, if updated knowledge, based on databases and registries,
shows that the variant can be considered as a low cancer risk TP53
variant and does not confer a high cancer risk in childhood:
• The index case has not developed a childhood cancer; and
• Childhood cancers have not been observed within the family; and
• This variant has not already been reported in other families with
childhood cancers; and
• This variant does not correspond to a dominant-negative missense variant
Recommendation 9 The testing in childhood of first-degree relatives of individuals with
germline disease-causing TP53 variants should be discussed with their
parents if cancers have occurred in early adulthood (before the age of
31 years) within the family, or if there is insufficient evidence in the
databases or registries to determine the childhood cancer risk.
• This discussion should address the burden, and uncertain benefits, of
surveillance in childhood, before a decision is made whether to test
the child for germline disease-causing TP53 variants.
Surveillance recommendations in carriers of
germline disease-causing TP53 variants
Recommendation 10 In children, clinical examination should be performed every
6 months, with specific attention to signs of virilization or early
puberty, and measurement of blood pressure
In adults, clinical examination should be performed annually with
specific attention, in patients who received radiotherapy, to
occurrence of basal cell carcinomas within the radiotherapy field
Recommendation 11 In adults, WBMRI without gadolinium enhancement should be
conducted annually
Recommendation 12 In individuals with high cancer risk TP53 variants or previously
treated by chemotherapy or radiotherapy, WBMRI without
gadolinium enhancement, should be conducted annually, from birth
Recommendation 13 In female individuals, breast MRI should be conducted annually,
from 20 years until 65 years
Recommendation 14 In children, from birth, and in adolescents (<18 years), abdominal
ultrasound for the detection of adrenocortical carcinoma should be
conducted at least every 6 months
Recommendation 15 In children, from birth, and in adolescents (<18 years), when
abdominal ultrasound does not allow a proper imaging of the adrenal
Table (continued)
glands, measurement of urine steroids, for detection of ACC, should
probably be conducted at least every 6 months
Recommendation 16 In adults until 50 years, brain MRI should be conducted annually
Recommendation 17 In individuals with high cancer risk TP53 variants, brain MRI should
be conducted from birth, annually
Recommendation 18 If surveillance includes brain MRI, at least the first (prevalence) scan
should be conducted using dedicated brain MRI with Gadolinium
enhancement
Recommendation 19 In children, if surveillance includes annual brain MRI, this should
alternate with the WBMRI, so that the brain is imaged at least every
6 months
Recommendation 20 Colonoscopy should be performed, from 18 years, every 5 years, only
if the carrier received abdominal radiotherapy for the treatment of a
previous cancer, or if there is a familial history of colorectal tumours
suggestive of an increased genetic risk
Guideline summary: surveillance protocol in carriers
of GERMLINE disease-causing TP53 variants
Exam Periodicity Age
to start
Age to end Condition Evidencea
Clinical examination
with, in children,
specific attention to
signs of virilisation
or early puberty and
measurement of
blood pressure and,
in patients who
received
radiotherapy, to
occurrence of basal
cell carcinomas
within the
radiotherapy field
Every
6 months
Birth 17 years Moderate
Annual 18 years – Moderate
Whole-Body MRI
without gadolinium
enhancement
Annual Birth – High cancer risk
TP53 variantb or
patient previously
treated by
chemotherapy or
radiotherapy
Moderate
18 years – Strong
Breast MRI Annual 20 years Until
65 years
Strong
Brain MRIc Annual Birth 18 years High cancer risk
TP53variant
Moderate
18 years Until
50 years
Moderate
Abdominal
ultrasound
Every
6 months
Birth Until
18 years
Strong
Urine steroids Every
6 months
Birth Until
18 years
When abdominal
ultrasound does not
allow a proper
imaging of the
adrenal glands
Weak
Colonoscopy Every
5 years
18 years – Only if the carrier
received abdominal
radiotherapy for the
treatment of a
previous cancer or if
there is a familial
history of colorectal
tumours suggestive
of an increased
genetic risk
Weak
aThis grading is based on published articles and expert consensus.
bA germline disease-causing TP53 variant should be considered as ‘high risk’ if the index
case has developed a childhood cancer; or childhood cancers have been observed within the
family; or this variant has already been detected in other families with childhood cancers; or
this variant corresponds to a dominant-negative missense variant.
cThe first scan should be conducted with I.V. Gadolinium enhancement; in children, brain
MRI should alternate with the Whole-Body MRI, so that the brain is imaged at least every
6 months.
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
Acknowledgements The authors deeply thank Matt Bolz-Johnson
and Tom Kenny for logistic support, coordination of the meetings
and permanent commitment for the elaboration of these guidelines.
They are grateful to the following colleagues for their critical review
of the guidelines: Prof. Lennart Blomqvist, Diagnostic Imaging
Unit, Karolinska University Hospital, Stockholm, Sweden;
Dr. Laurence Brugières, Department of Paediatrics and Adolescents
Oncology, Gustave Roussy, Villejuif, France; Dr. Suzette Delaloge,
Department of Medical Oncology, Gustave Roussy, Villejuif,
France; Dr. Christian Kratz, Paediatric Haematology and Oncology,
Medical School, Hannover, Germany. They also acknowledge the
following colleagues for fruitful discussions and suggestions: Prof.
Stefan Aretz, University Hospital, Bonn, Germany; Dr. Ignacio
Blanco, Institut Català de la Salut, Barcelona, Spain; Prof.Maurizio
Genuardi, Fondazione Policlinico Universitario A. Gemelli, Roma,
Italy; Prof. Elke Holinski Feder, Medizinisch Genetisches Zentrum,
München, Germany; Prof. Jan Lubinski, Pomeranian Medical Uni-
versity - University Clinical Hospital, Szczecin, Poland; Dr. Hector
Salvador, Hospital Sant Joan de Déu, Barcelona, Spain;
Dr. Katharina Wimmer, Division of Human Genetics, Medical
University Innsbruck, Innsbruck, Austria; Dr Emma Woodward,
St Mary’s Hospital, Central Manchester University Hospitals NHS
Foundation Trust, Manchester, UK. This guideline has been sup-
ported by the European Reference Network on Genetic Tumour Risk
Syndromes (ERN GENTURIS) - Project ID No 739547. ERN
GENTURIS is partly co-funded by the European Union within the
framework of the Third Health Programme ‘ERN-2016 – Frame-
work Partnership Agreement 2017–2021’.
The European Reference Network GENTURIS Nicoline Hoogerbrugge6,
Marjolijn Ligtenberg6, Marleen Kets6,7, Rianne Oostenbrink8, Rolf
Sijmons9, Gareth Evans10, Emma Woodward10, Marc Tischkowitz11,
Eamonn Maher11, Rosalie E. Ferner12, Stefan Aretz13, Isabel Spier14,
Verena Steinke-Lange14, Elke Holinski-Feder14, Evelin Schröck15,
Thierry Frebourg16, Claude Houdayer16, Chrystelle Colas17,
Pierre Wolkenstein18, Vincent Bours19, Eric Legius20, Bruce Poppe21,
Kathleen Claes21, Robin de Putter21, Ignacio Blanco Guillermo22,
Gabriel Capella22, Joan Brunet Vidal22, Conxi Lázaro22, Judith
Balmaña22, Hector Salvador Hernandez23, Carla Oliveira24, Manuel
Teixeira24, Svetlana Bajalica Lagercrantz25, Emma Tham25,
Jan Lubinski26, Karolina Ertmanska26, Bela Melegh27, Mateja Krajc28,
Ana Blatnik28, Sirkku Peltonen29, Marja Hietala29.
6Radboud University Medical Center, Nijmegen, The Netherlands;
7NKI Antoni van Leeuwenhoek hospital, Amsterdam, The Nether-
lands; 8Erasmus Medical Center, Rotterdam, The Netherlands; 9Uni-
versity Medical Center, Groningen, The Netherlands; 10Genomic
Medicine, Central Manchester Foundation Trust, Manchester, UK;
11Cambridge University Hospitals NHS Foundation Trust,
Cambridge, UK; 12Guy’s and St. Thomas’ NHS Foundation Trust,
London, UK; 13University Hospital Bonn, Bonn, Germany; 14Medi-
zinisch Genetisches Zentrum, Munich, Germany; 15Hereditary Cancer
Syndrome Center Dresden, Dresden, Germany; 16Rouen University
Hospital, Rouen, France; 17Institut Curie, Paris, France; 18University
Hospital Henri Mondor-National Referral Center, Créteil, France;
19University Hospital, Liege, Belgium; 20University Hospital Leuven,
Leuven, Belgium; 21Ghent University Hospital, Ghent, Belgium;
22Hospital Universitari Germans Trias i Pujol y ICO Badalona, lnstitut
Catala d’Oncologia, Barcelona, Spain; 23Hospital Sant Joan de Déu,
Barcelona, Spain; 24Porto Comprehensive Cancer Center,
Porto, Portugal; 25Karolinska University Hospital,
Stockholm, Sweden; 26Pomeranian Medical University - University
Clinical Hospital n1, Szczecin, Poland; 27University of Pécs,
Pécs, Hungary; 28Institute of Oncology, Ljubljana, Slovenia; 29Turku
University Hospital, Turku, Finland
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Disclaimer The content of these guidelines represents the views of the
authors only and it is their sole responsibility; it cannot be considered
to reflect the views of the European Commission and/or the Con-
sumers, Health, Agriculture and Food Executive Agency (CHAFEA)
or any other body of the European Union. The European Commission
and the Agency do not accept any responsibility for use that may be
made of the information it contains.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and
other neoplasms. A familial syndrome? Ann Intern Med. 1969;71:
747–52.
2. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim
DH, et al. Germ line p53 mutations in a familial syndrome of
breast cancer, sarcomas, and other neoplasms. Science. 1990;250:
1233–8.
3. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-
line transmission of a mutated p53 gene in a cancer-prone family
with Li-Fraumeni syndrome. Nature. 1990;348:747–9.
4. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY,
Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical
characteristics of families with p53 germline mutations. J Clin
Oncol. 2009;27:1250–6.
5. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH,
Hogervorst FB, et al. TP53 germline mutation testing in 180
families suspected of Li-Fraumeni syndrome: mutation detection
rate and relative frequency of cancers in different familial phe-
notypes. J Med Genet. 2010;47:421–8.
6. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fer-
mey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from
TP53 mutation carriers. J Clin Oncol. 2015;33:2345–52.
7. Varley JM, McGown G, Thorncroft M, James LA, Margison GP,
Forster G. Are there low-penetrance TP53 Alleles? evidence from
childhood adrenocortical tumors. Am J Hum Genet. 1999;65:
995–1006.
8. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin
D. High frequency of germline p53 mutations in childhood
adrenocortical cancer. J Natl Cancer Inst. 1994;86:1707–10. 16
9. Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC,
Rodriguez-Galindo C, Zambetti GP, et al. Prevalence and
T. Frebourg et al.
functional consequence of TP53 mutations in pediatric adreno-
cortical carcinoma: a children’s oncology group study. J Clin
Oncol. 2015;33:602–9.
10. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, et al.
TP53 alterations determine clinical subgroups and survival of
patients with choroid plexus tumors. J Clin Oncol. 2010;28:
1995–2001.
11. Hettmer S, Archer NM, Somers GR, Novokmet A, Wagers AJ,
Diller L, et al. Anaplastic rhabdomyosarcoma in TP53 germline
mutation carriers. Cancer. 2014;120:1068–75.
12. Fortuno C, James PA, Spurdle AB. Current review of TP53
pathogenic germline variants in breast cancer patients outside Li-
Fraumeni syndrome. Hum Mutat. 2018;39:1764–73.
13. Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D,
et al. High frequency of de novo mutations in Li-Fraumeni syn-
drome. J Med Genet. 2009;46:689–93.
14. Renaux-Petel M, Charbonnier F, Théry JC, Fermey P, Lienard G,
Bou J, et al. Contribution of de novo and mosaic TP53 mutations
to Li-Fraumeni syndrome. J Med Genet. 2018;55:173–80.
15. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L,
et al. The genomic landscape of hypodiploid acute lymphoblastic
leukemia. Nat Genet. 2013;45:242–52.
16. Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al.
TP53 Germline variations influence the predisposition and prog-
nosis of B-cell acute lymphoblastic leukemia in children. J Clin
Oncol. 2018;36:591–9.
17. Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C,
Groebner S, et al. Spectrum and prevalence of genetic predis-
position in medulloblastoma: a retrospective genetic study and
prospective validation in a clinical trial cohort. Lancet Oncol.
2018;19:785–98.
18. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al.
Understanding the function-structure and function-mutation rela-
tionships of p53 tumor suppressor protein by high-resolution
missense mutation analysis. Proc Natl Acad Sci USA.
2003;100:8424–9.
19. Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg
T, et al. Germline TP53 mutations result into a constitutive defect
of p53 DNA binding and transcriptional response to DNA
damage. Hum Mol Genet. 2017;26:2591–602.
20. Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M,
Kim J, et al. Mutational processes shape the landscape of TP53
mutations in human cancer. Nat Genet. 2018;50:1381–7.
21. Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O,
Gershoni A, et al. A systematic p53 mutation library links dif-
ferential functional impact to cancer mutation pattern and evolu-
tionary conservation. Mol Cell. 2018;71:178–90.
22. Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A, Jonsson
P. Therapy-related clonal hematopoiesis in patients with non-
hematologic cancers is common and associated with adverse
clinical outcomes. Cell Stem Cell. 2017;21:374–82.e4.
23. Weber-Lassalle K, Harter P, Hauke J, Ernst C, Kommoss S,
Marmé F, et al. Diagnosis of Li-Fraumeni syndrome: differ-
entiating TP53 germline mutations from clonal hematopoiesis:
results of the observational AGO-TR1 trial. Hum Mutat.
2018;39:2040–6.
24. Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H,
Blazer KR, et al. Somatic TP53 variants frequently confound
germ-line testing results. Genet Med. 2018;20:809–16.
25. Chen S, Liu Y. p53 involvement in clonal hematopoiesis of
indeterminate potential. Curr Opin Hematol. 2019;4:235–40.
26. Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-
Freichey F, Abel A, et al. P53 germline mutations in childhood
cancers and cancer risk for carrier individuals. Br J Cancer.
2000;82:1 932–7.
27. Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT,
et al. Risks of first and subsequent cancers among TP53 mutation
carriers in the National Cancer Institute Li-Fraumeni syndrome
cohort. Cancer. 2016;122:3673–81.
28. Amadou A, Waddington Achatz MI, Hainaut P. Revisiting tumor
patterns and penetrance in germline TP53 mutation carriers:
temporal phases of Li-Fraumeni syndrome. Curr Opin Oncol.
2018;30:23–29.
29. de Andrade KC, Frone MN, Wegman-Ostrosky T, Khincha PP,
Kim J, Amadou A, et al. Variable population prevalence estimates
of germline TP53 variants: a gnomAD-based analysis. Hum
Mutat. 2019;40:97–105.
30. Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI,
et al. Penetrance of different cancer types in families with Li-
Fraumeni syndrome: a validation study using multi-center cohorts.
Cancer Res. 2019. https://doi.org/10.1158/0008-5472.CAN-19-
0728.
31. Wong P, Verselis SJ, Garber JE, Schneider K, DiGianni L,
Stockwell DH, et al. Prevalence of early onset colorectal cancer in
397 patients with classic Li-Fraumeni syndrome. Gastro-
enterology. 2006;130:73–9.
32. Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM,
et al. Germline TP53 mutations in patients with early-onset col-
orectal cancer in the colon cancer family registry. JAMA Oncol.
2015;1:214–21.
33. MacFarland SP, Zelley K, Long JM, McKenna D, Mamula P,
Domchek SM, et al. earlier colorectal cancer screening may be
necessary in patients with Li-Fraumeni syndrome. Gastro-
enterology. 2019;15:273–4.
34. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C,
Liu W, et al. Penetrance of adrenocortical tumours associated with
the germline TP53 R337H mutation. J Med Genet. 2006;43:91–6.
35. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A,
Rossi BM, et al. The TP53 mutation, R337H, is associated with
Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian famil-
ies. Cancer Lett. 2007;245:96–102.
36. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M,
Martel-Planche G, et al. Detection of R337H, a germline TP53
mutation predisposing to multiple cancers, in asymptomatic
women participating in a breast cancer screening program in
Southern Brazil. Cancer Lett. 2008;261:21–5.
37. Kasper E, Angot E, Colasse E, Nicol L, Sabourin JC, Adriouch S,
et al. Contribution of genotoxic anticancer treatments to the
development of multiple primary tumours in the context of
germline TP53 mutations. Eur J Cancer. 2018;101:254–62.
38. Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H,
et al. Biochemical and imaging surveillance in germline TP53
mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a
prospective observational study. Lancet Oncol. 2016;17:1295–305.
39. Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer
MC, et al. Cancer screening recommendations for individuals with
Li-Fraumeni syndrome. Clin Cancer Res. 2018;23:e38–e45.
40. Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA,
et al. Baseline surveillance in Li-Fraumeni syndrome using whole-
body magnetic resonance imaging: a meta-analysis. JAMA Oncol.
2017;3:1634–9.
41. Caron O, Frebourg T, Benusiglio PR, Foulon S, Brugières L.
Lung adenocarcinoma as part of the Li-Fraumeni syndrome
spectrum: preliminary data of the LIFSCREEN randomized clin-
ical trial. JAMA Oncol. 2017;3:1736–7.
42. Ruijs MWG, Loo CE, van Buchem CAJM, Bleiker EMA, Sonke
GS. Surveillance of Dutch patients with Li-Fraumeni syndrome:
the LiFe-Guard study. JAMA Oncol. 2017;3:1733–4.
43. Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J,
et al. Baseline results from the UK SIGNIFY study: a whole-body
Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromes
MRI screening study in TP53 mutation carriers and matched
controls. Fam Cancer. 2017;16:433–40.
44. Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS,
Willis BJ, et al. Whole body magnetic resonance imaging (WB-
MRI) and brain MRI baseline surveillance in TP53 germline
mutation carriers: experience from the Li-Fraumeni Syndrome
Education and Early Detection (LEAD) clinic. Fam Cancer
2018;17:287–94.
45. O’Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C,
Itriago-Araujo E, et al. Screening with whole-body magnetic
resonance imaging in pediatric subjects with Li-Fraumeni
syndrome: A single institution pilot study. Pediatr. Blood Cancer.
2018;65. https://doi.org/10.1002/pbc.26822.
46. Paixao D, Guimaraes MD, de Andrade KC, Nobrega AF, Choj-
niak R, Achatz MI. Whole-body magnetic resonance
imaging of Li-Fraumeni syndrome patients: observations from a
two rounds screening of Brazilian patients. Cancer Imaging.
2018;18:27.
47. Layne KA, Dargan PI, JRH Archer, Wood DM. Gadolinium
deposition and the potential for toxicological sequelae—a litera-
ture review of issues surrounding gadolinium-based contrast
agents. Br J Clin Pharm. 2018;84:2522–34.
T. Frebourg et al.
